Skip to content Skip to footer
Subscribe Now
NEWS

Eli Lilly to Acquire AtaiBeckley for $3.8B

Shots: Eli Lilly has entered into a definitive agreement to acquire AtaiBeckley, incl. its asset, BPL-003 (mebufotenin benzoate) & VLS-01 (buccal film formulation of DMT) to treat treatment-resistant depression; closing expected in Q3’26 Lilly will acquire AtaiBeckley for $6.75/share, plus a CVR of ~$2.5/share tied to development & regulatory milestones for BPL-003 & VLS-01. The…
July 16, 2026

Read more

VIEWPOINTS

A New Era in Neuropsychiatry: Dr. Velichka Valcheva on GH Research’s Rapid-Acting Breakthrough, GH001

Shots:   GH001, an inhaled formulation of mebufotenin, is emerging as a highly differentiated therapy for treatment-resistant depression, delivering ultra-rapid and profound symptom improvement – patients come to the clinic depressed and many leave in remission already on the same day. Long term, in a Phase 2b trial, 73% of patients who completed six months were in remission—substantially higher than the…
February 23, 2026

Read more

Viewpoints_Erika Ross
VIEWPOINTS

Erika Ross, Director of Clinical & Applied Research at Abbott Shares Insights on FDA Breakthrough Device Designation to Explore its DBS System to Treat Treatment-Resistant Depression

Shots:  Erika spoke about the FDA Breakthrough Device Designation received by Abbott to investigate its deep brain stimulation (DBS) system to treat treatment-resistant depression (TRD) Erika also talked about how NeuroSphere Virtual Clinic is compatible with the  deep brain stimulation (DBS) system  The interview gives an understanding of Abbott’s vision to bring life-changing technologies in…
October 5, 2022

Read more